Healthcare provider profile · identity verified

Mark Hryniewich, MD

General Practice · LEOMINSTER, MA · NPI 1255307781

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	441	237
Lisinopril	Lisinopril	168	88
Amlodipine Besylate	Amlodipine Besylate	157	73
Omeprazole	Omeprazole	146	69
Losartan Potassium	Losartan Potassium	141	79
Levothyroxine Sodium	Levothyroxine Sodium	113	63
Metformin Hcl	Metformin Hcl	98	61
Gabapentin	Gabapentin	96	52
Rosuvastatin Calcium	Rosuvastatin Calcium	92	49
Metoprolol Succinate	Metoprolol Succinate	86	48
Furosemide	Furosemide	79	37
Albuterol Sulfate Hfa	Albuterol Sulfate	77	50
Lorazepam	Lorazepam	74	43
Tamsulosin Hcl	Tamsulosin Hcl	68	29
Hydrochlorothiazide	Hydrochlorothiazide	66	34
Trazodone Hcl	Trazodone Hcl	66	36
Eliquis	Apixaban	63	27
Simvastatin	Simvastatin	60	29
Sertraline Hcl	Sertraline Hcl	51	30
Pantoprazole Sodium	Pantoprazole Sodium	50	24
Valsartan	Valsartan	50	24
Metformin Hcl Er	Metformin Hcl	48	34
Famotidine	Famotidine	47	20
Atenolol	Atenolol	44	23
Citalopram Hbr	Citalopram Hydrobromide	44	20
Ibuprofen	Ibuprofen	43	25
Chlorthalidone	Chlorthalidone	42	16
Alendronate Sodium	Alendronate Sodium	41	20
Metoprolol Tartrate	Metoprolol Tartrate	41	22
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	39	27
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	35	19
Tramadol Hcl	Tramadol Hcl	35	20
Ozempic	Semaglutide	33	13
Warfarin Sodium	Warfarin Sodium	33	16
Clonazepam	Clonazepam	32	17
Allopurinol	Allopurinol	31	19
Mirtazapine	Mirtazapine	31	12
Alprazolam	Alprazolam	30	17
Escitalopram Oxalate	Escitalopram Oxalate	30	19
Pravastatin Sodium	Pravastatin Sodium	30	19
Clopidogrel	Clopidogrel Bisulfate	29	12
Ezetimibe	Ezetimibe	28	13
Oxycodone Hcl	Oxycodone Hcl	28	17
Fluticasone Propionate	Fluticasone Propionate	27	17
Glipizide	Glipizide	27	18
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	27	12
Potassium Chloride	Potassium Chloride	27	16
Fluoxetine Hcl	Fluoxetine Hcl	26	12
Finasteride	Finasteride	24	11
Jardiance	Empagliflozin	24	14
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	24	12
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	23	suppressed
Mounjaro	Tirzepatide	22	15
Trulicity	Dulaglutide	22	suppressed
Duloxetine Hcl	Duloxetine Hcl	19	11
Paroxetine Hcl	Paroxetine Hcl	18	suppressed
Spironolactone	Spironolactone	18	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	18	suppressed
Buspirone Hcl	Buspirone Hcl	17	11
Betamethasone Diprop Augmented	Betamethasone/Propylene Glyc	16	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	16	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	16	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	16	suppressed
Carvedilol	Carvedilol	15	suppressed
Humalog Kwikpen U-100	Insulin Lispro	15	suppressed
Januvia	Sitagliptin Phosphate	15	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	14	suppressed
Bupropion Xl	Bupropion Hcl	14	suppressed
Diclofenac Sodium	Diclofenac Sodium	14	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	13	suppressed
Meclizine Hcl	Meclizine Hcl	13	suppressed
Montelukast Sodium	Montelukast Sodium	13	suppressed
Naproxen	Naproxen	13	suppressed
Tiadylt Er	Diltiazem Hcl	13	suppressed
Breo Ellipta	Fluticasone/Vilanterol	12	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	12	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	11	suppressed
Baclofen	Baclofen	11	suppressed
Clonidine	Clonidine	11	suppressed
Clonidine Hcl	Clonidine Hcl	11	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	11	suppressed
Lactulose	Lactulose	11	suppressed
Nystatin	Nystatin	11	suppressed
Ondansetron Hcl	Ondansetron Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error